Pharmaceutical Technology

MAY 30, 2023

SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. The authorisation allows the distribution of the vaccine in Scotland, Wales and England.

Vaccination 298

Vaccination Vaccine Protein Medicine 298

Pharmaceutical Technology

NOVEMBER 17, 2023

million doses of its omicron-adapted mRNA vaccine for Covid-19. Daiichi Sankyo has signed an agreement with Japan's MHLW to deliver 1.4

Vaccination 235

Vaccination Vaccine 235

Pharmaceutical Technology

MARCH 28, 2023

Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. The company saw major successes with its Covid-19 vaccine, developed in collaboration with Pfizer. In response to the lower vaccine sales forecasts, BioNTech shares opened at 3.9%

Vaccination 276

Vaccination Vaccine Clinical Trials Clinical Trials 276

Pharmaceutical Technology

NOVEMBER 28, 2023

adapted monovalent mRNA vaccine as a booster for Covid-19. Japan’s MHLW has granted approval for Daiichi Sankyo’s Omicron XBB.1.5-adapted

Vaccination 147

Vaccination Vaccine 147

Pharmaceutical Technology

APRIL 19, 2023

The US Food and Drug Administration (FDA) has made changes to the emergency use authorisations (EUAs) of the Pfizer -BioNTech and Moderna bivalent mRNA Covid-19 vaccines. The latest amendment aims to simplify the vaccination schedule for most people. The changes mean that the current bivalent vaccines for the original and Omicron BA.4/BA.5

Vaccination 334

Vaccination Vaccine Gene Therapy Gene 334

Pharmaceutical Technology

NOVEMBER 29, 2023

Japan’s MHLW has approved CSL and Arcturus Therapeutics’ self-amplifying mRNA (sa-mRNA) Covid-19 vaccine, ARCT-154.

Vaccination 173

Vaccination Vaccine 173

Pharmaceutical Technology

NOVEMBER 28, 2023

The emergency use listing is based on non-clinical data where the vaccine demonstrated immune responses against variants in SARS-CoV-2.

Vaccination 165

Vaccination Vaccine Immune Response 165

Pharmaceutical Technology

NOVEMBER 28, 2023

Emergent’s Cyfendus was approved by the US FDA as a post-exposure prophylactic vaccine for anthrax in July.

Vaccination 162

Vaccination Vaccine 162

Pharmaceutical Technology

MARCH 14, 2023

The National Health Surveillance Agency (ANVISA) in Brazil has granted approval for Takeda ’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). The vaccine has received approval for preventing dengue disease in people aged four years to 60 years.

Vaccination 286

Vaccination Vaccine Clinical Trials Clinical Trials 286

Pharmaceutical Technology

APRIL 14, 2023

Ghana’s Food and Drug Authority (FDA) has approved R21/Matrix-M malaria vaccine in children aged 5 to 36 months, marking the first regulatory clearance for the University of Oxford-developed vaccine in any country in the world. Children between the ages of five and 36 months are at highest risk of death from malaria.

Vaccination 279

Vaccination Vaccine Drugs Trials 279

Pharmaceutical Technology

NOVEMBER 15, 2023

Chief executive Amanda Pritchard says vaccination and screening could make eliminating cervical cancer a reality in the next two decades.

Vaccination 246

Vaccination Vaccine 246

Pharmaceutical Technology

OCTOBER 10, 2023

The Gates Foundation is providing $40m in funding to advance the accessibility of Quantoom Biosciences' affordable mRNA vaccine platform.

Vaccination 233

Vaccination Vaccine 233

Pharmaceutical Technology

FEBRUARY 7, 2023

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Takeda ’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]). The vaccine candidate has been approved for active immunisation against the infection in people from four years of age.

Vaccination 264

Vaccination Vaccine Genetics Trials 264

Pharmaceutical Technology

OCTOBER 9, 2023

GSK and Chongqing Zhifei have signed an exclusive agreement for co-promoting the former’s shingles vaccine, Shingrix, in China.

Vaccination 276

Vaccination Vaccine 276

Pharmaceutical Technology

JUNE 9, 2023

5+delta) protein vaccine (Sf9 cell). This marks the world’s first Covid-19 vaccine approved for emergency use against XBB descendent lineages of SARS-CoV-2. The vaccine has been developed by WestVac Biopharma along with the West China Medical Center and Sichuan University. recombinant Covid-19 trivalent (XBB.1.5+BA.5+delta)

Vaccination 269

Vaccination Vaccine Protein Antibody 269

Pharmaceutical Technology

APRIL 3, 2023

The World Health Organisation (WHO) has revised its recommendations regarding the use of Covid-19 vaccines following a meeting of the agency’s Strategic Advisory Group of Experts on Immunisation (SAGE). The panel emphasised that the extra booster dose recommendation only pertains to one shot and is not for continued annual booster vaccines.

Vaccination 278

Vaccination Vaccine 278

AuroBlog - Aurous Healthcare Clinical Trials blog

OCTOBER 8, 2023

The World Health Organization has approved a new vaccine that scientists argue will be a game-changer in the fight against malaria, which kills half a million people in Africa every year.

Vaccination 201

Vaccination Vaccine Trials Scientist 201

Pharmaceutical Technology

SEPTEMBER 12, 2023

adapted monovalent Covid-19 vaccine, COMIRNATY 2023-2024 Formulation. The US FDA has approved Pfizer and BioNTech’s sBLA for Omicron XBB.1.5-adapted

FDA Approval 278

FDA Approval Vaccination Vaccine 278

Bio Pharma Dive

JANUARY 23, 2023

Agency scientists are proposing to update COVID shots once a year to match circulating coronavirus strains, as well as simplifying current vaccination regimens.

Vaccination 319

Vaccination Vaccine Scientist 319

Pharmaceutical Technology

SEPTEMBER 8, 2023

The European Commission granted expanded indication approval for Merck’s Ebola vaccine, Ervebo, to include children aged one year or above.

Vaccination 241

Vaccination Vaccine 241

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Pharmaceutical Technology

APRIL 11, 2023

The US government is reportedly investing more than $5bn in a programme to accelerate the development of new Covid-19 vaccines and treatments. Health experts have lent their support to the new programme as the existing vaccines may not be as effective against future virus threats.

Vaccination 264

Vaccination Vaccine Development Antibody 264

AuroBlog - Aurous Healthcare Clinical Trials blog

AUGUST 3, 2023

An experimental vaccine that aims to slow down or prevent the progression of Alzheimer’s disease has been trialed in mice with promising early results. Mice engineered with genes that put them at greater risk of an Alzheimer’s-like disease had fewer amyloid plaques following the vaccine.

Vaccination 224

Vaccination Vaccine Gene Trials 224

Pharmaceutical Technology

OCTOBER 2, 2023

The Physiology and Medicine Prize has gone to two researchers whose work laid the foundation for Pfizer and Moderna’s Covid-19 vaccines.

Vaccination 257

Vaccination Vaccine Research Medicine 257

World of DTC Marketing

JULY 20, 2021

29 percent of Americans said they were unlikely to get vaccinated — up from 24 percent three months earlier. Most workers do not want their own employer to require vaccination, including the vast majority of unvaccinated workers (92%). Yet even as evidence grows that vaccines are safe and effective, resistance to them is also growing.

Vaccination 309

Vaccination Vaccine Pharma Companies Allergies 309

Drug Discovery World

NOVEMBER 24, 2023

The University of Queensland’s re-engineered clamp platform has produced a vaccine that is equally safe and virus-neutralising as an approved Covid vaccine considered among the best in its class. He said: “CEPI is striving towards vaccines being developed within 100 days of a new virus emerging: a goal known as the 100 Days Mission.

Clinical Trials 110

Clinical Trials Clinical Trials Vaccination Vaccine 110

Pharmaceutical Technology

JUNE 20, 2023

Teenagers and adults under the age of 25 at higher risk of sexually transmitted disease transmission will receive a single dose of the human papillomavirus (HPV) vaccine from September 2023. The shift by the UK Health Security Agency (UKHSA) follows moves already made by Scotland and Wales to half the HPV vaccine dose.

Vaccination 264

Vaccination Vaccine Development 264

Pharmaceutical Technology

OCTOBER 26, 2023

A pivotal Phase III trial will be initiated in the coming months to further evaluate the lead formulations of the combination vaccine.

Vaccination 241

Vaccination Vaccine Trials 241

Pharmaceutical Technology

NOVEMBER 15, 2023

The UK JCVI has recommended the addition of chickenpox vaccine to the country's routine immunisation programme for children.

Vaccination 162

Vaccination Vaccine 162

Pharmaceutical Technology

JUNE 6, 2023

Oragenics has secured funding from the Canadian bioresearch consortium CQDM to develop a variant-agnostic protein antigen for use in its Covid-19 intranasal vaccine. In March 2023, Oragenics and Inspirevax entered an exclusive global licence deal to develop the former’s lead intranasal Covid-19 vaccine candidate, NT-CoV2-1.

Vaccination 231

Vaccination Vaccine Development Protein 231

Bio Pharma Dive

FEBRUARY 10, 2023

The pharma and partner BioNTech have kicked off the first human trial of a messenger RNA shot for shingles, believing there’s room to clear the high bar set by GSK’s rival vaccine.

Vaccination 358

Vaccination Vaccine RNA Trials 358

Pharmaceutical Technology

DECEMBER 7, 2022

Health Canada has granted approval for a supplement to a New Drug Submission (sNDS) of Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted), Nuvaxovid (NVX-CoV2373), for use in adolescents aged 12 to 17 years. The trial is designed to analyse the safety and effectiveness of the vaccine.

Vaccination 264

Vaccination Vaccine Clinical Trials Clinical Trials 264

Bio Pharma Dive

OCTOBER 31, 2023

The pharma’s shot Abrysvo made over $300 million in sales during the first few months of its launch, and will be an important product to help offset declining COVID vaccine sales.

Vaccination 180

Vaccination Vaccine Marketing Sales 180

Bio Pharma Dive

MAY 31, 2023

The shot’s clearance comes several weeks after the regulator made GSK’s Arexvy the first vaccine for RSV in the U.S.

FDA Approval 315

FDA Approval Vaccination Vaccine Regulation 315

AuroBlog - Aurous Healthcare Clinical Trials blog

AUGUST 28, 2023

India’s success story in pediatric vaccination programme should be further replicated in the form of adult vaccination programme, experts recommended on the occasion of the 2nd edition of the India Vaccine Leaders Conclave (IVLC) held between August 22 and August 23, 2023 under the theme “Building Resilient Vaccine Ecosystems” in Mumbai.

Vaccination 150

Vaccination Vaccine Clinical Trials Clinical Trials 150

Pharmaceutical Technology

JUNE 16, 2023

France-based biotech company Osivax has thrown its hat into the influenza ring by dosing the first subject with its vaccine candidate OVX836. The Phase IIa trial (NCT05734040) in Australia will see a potential 500 volunteers given OVX836 in combination with quadrivalent influenza vaccines (QIVs).

Vaccination 246

Vaccination Vaccine Trials Clinical Trials 246

Pharmaceutical Technology

DECEMBER 11, 2022

The US Food and Drug Administration (FDA) has granted Fast Track designation for Pfizer and BioNTech’s messenger ribonucleic acid (mRNA)-based combination vaccine candidate against Covid-19 and influenza. The vaccine is intended to prevent two respiratory ailments through a single injection. 5 Omicron sublineages spike proteins.

Vaccination 289

Vaccination Vaccine Gene Therapy Gene 289